Marie Curie Post Doc position in Instituto de Investigación Biomédica de Málaga (IBIMA). Inflammation and Cardiovascular Disease: Translational Studies

HOSTING SUMMARY

The Heart Failure, Ischemic Cardiopathy and Valvulopathy research group at the Biomedical Research Institute of Málaga - IBIMA (Málaga, Spain) is interested in hosting a Marie Curie Fellowship. Two Marie Skłodowska-Curie projects are offered to be supervised by Dr. Francisco Javier Pavón. The hosting group belongs to the Cardiology and Cardiac Surgery Unit at Hospital Universitario Virgen de la Victoria and is part of the Cardiovascular Diseases Networking Biomedical Research Center - CIBERCV (funded by the National Health Agency) from 2008. Dr. Jiménez Navarro is the coordinator of the research group, which develops clinical and preclinical studies from a translational perspective with a multidisciplinary staff that combines scientific, academic and clinical activities. Dr. Pavón has been working in numerous basic and clinical studies focused on the characterization of inflammatory signaling systems (e.g., cytokines, chemokines, growth factors and fatty acid-derived mediators such as endocannabinoids) associated with obesity, addiction and common comorbidities, mainly psychopathologies and cardiovascular diseases. The main objective of these studies has been the identification of potential biomarkers and the development of pharmacological tools to improve the prognosis, diagnosis and/or treatment of the patients. Dr. Pavón is currently management committee member from Spain of the COST action CA15135 –MuTaLig. In addition, he participates as researcher in the Spanish Network for Addictive Disorders from 2010. His wide scientific career is supported by more than 100 peer-reviewed articles (indexed in Pubmed), 5 patents with PCT extension, 5 projects as PI and more than 30 projects as collaborator (2 European projects: REPROBESITY - HEALTH-F2-2008-223713 and FATZHEIMER - EULACH16/T01-0131) and supervision of 4 PhD students.

HOSTING DETAILS

Description of the center:

The IBIMA is a space for multidisciplinary biomedical research that gather the resources, skills and expertise of the main public University Hospitals, Primary Care Centers and the University of Málaga to constitute a strong collaborative structure (www.ibima.eu/en). The institute promotes translational research in order to accelerate the transference of the scientific breakthroughs into the health care system through the improvement of the prevention, diagnosis and treatment. The IBIMA has been accredited as a Health Research Institute since January 15th, 2015 by the Carlos III Health Institute (National Health Agency), on the basis of the Spanish Royal Decree 339/2004 of February 27th. It has a workforce of about 900 people, with more than 700 researchers, 114 technicians and 34 managers, clustered in 44 consolidated groups, 4 emergent groups and 7 associated groups. The IBIMA performs research activities within the scope of the Andalusian Health System - SAS (Servicio Andaluz de Salud), which belongs to the Ministry of Health and Families of the Government of Andalusia (Junta de Andalucía), in the South of Spain. Its mission is to provide a high-quality healthcare system to the citizens of Andalusia seeking efficiency and optimization of the use of public resources. At Málaga province, the SAS provides care to a population of 1,600,000 habitants coordinating the services of 2 university hospitals (Hospital Regional Universitario de Málaga and Hospital Universitario Virgen de la Victoria) and 48 primary care centers in the city of Málaga together with those services located throughout the rural area of the province (4 hospitals and 107 primary care centers).

The IBIMA Strategic Plan 2018-2022 defines the evolution of the Institute taking into account the European, national and regional research policies, welcoming the collaboration with private entities and analyzing the province health indicators to establish the course of actions to become a scientific and technological reference for Málaga and the international community. The backbone of the IBIMA organization has been the prioritization of the lines of research pursuing the greatest impact on the health of the citizens. The institute is structured around 4 priority and 2 transversal research areas, where the research groups, the common research facilities (Estructuras comunes de apoyo a la investigación, ECAI) and the research support units (Unidades de apoyo a la Investigación, UAI) are coordinated for the execution and the management of the research.

• Research areas:

1 Cardiovascular diseases, obesity and diabetes. Environmental determinants and lifestyle

2 Oncology and hematology

3 Neurosciences, chronicity, aging and health in vulnerable populations

4. Autoimmune, infectious diseases, inflammation and allergy

5. Transversal 1. IBIMA Rare: Rare diseases

6. Transversal 2. IBIMA Tech: Technology area in health and Innovation

• Common research facilities (ECAI):

1. Clinical studies 6. Microscopy

2. Biobank 7. Cellular biology (cytometry and cultures)

3. Bioinformatics 8. Cell production and GMP rooms

4. Animal research 9. Proteomics

5. Genomics 10. Methodological and statistical advice

• Research support units (UAI):

1. Quality, monitoring and evaluation

2. Project management

3. International projects

4. Innovation and technology transfer

In addition, the IBIMA Training Plan 2018 - 2022 defines the aims and objectives regarding the training of staff providing seminars, courses and events designed to promote and assure high-quality scientific and technical knowledge. Furthermore, the IBIMA collaborates with the University of Málaga through post-grade doctoral programs and masters in life science and health.

The integral management and promotion of research & development and innovation for the IBIMA are provided by the Andalusian Public Foundation for Health and Biomedicine Research in Málaga – FIMABIS. The FIMABIS is a non-profit foundation that is independent of the governing structures of the IBIMA partners, which allows an efficient economic and administrative management that complies with the regional, national and international governmental-public and private funding agencies normative.

In July 2017, the European Commission awarded IBIMA - FIMABIS the HRS4R Seal in recognition of the commitment acquired in implementing the principles of the "European Charter of Researcher and Code of Conduct in the Recruitment of Researchers " through its HRS4R strategy Implementation Plan.

Description of the group:

The Heart Failure and Ischemic Cardiopathy group of the Cardiology and Cardiac Surgery Unit at the Hospital Universitario Virgen de la Victoria belongs to the IBIMA research area 1 (Cardiovascular diseases, obesity and diabetes. Environmental determinants and lifestyle). The group is led by Dr. Jiménez-Navarro, cardiologist and professor at University of Málaga with a strong experience in the integration of basic and clinical research and the implementation of translational approaches in the unit. This is a multidisciplinary group that includes postdoctoral and predoctoral researchers (cardiologists, biologists, psychologists...), nurses and lab technicians. There are 3 main research lines:

1. Clinical efficiency of new percutaneous treatments for structural heart diseases

2. Strategies for the prevention, diagnosis and treatment of coronary heart disease

3. Cardiovascular translational research: genetics and cardiovascular disease

Regarding the participation in collaborative scientific structures, the hosting group is part of the Cardiovascular Diseases Networking Biomedical Research Center - CIBERCV from 2008 and the Network of Addictive Disorders - RTA from 2010. Both CIBERCV and RTA are funded by the National Health Agency.

Description of the project/projects:

The project proposals are as follows:

• Project 1 Objective: Characterization of inflammatory signaling systems in cardiovascular tissue (myocardial muscle and epi/pericardial fat) and blood after a chronic exposure to drugs and/or hypercaloric diets. Experimental animals.
• Project 2 Objective: Clinical evaluation of patients with ischemia that requires myocardial revascularization and determination of inflammatory and myocardial damage markers in the blood: Elaboration of predictive models of prognosis in ischemic patients treated with complete or incomplete revascularization. Humans.

Description Principal Investigator (education, research experience, publications, projects, ORCID ID, Researcher ID or other, etc.)

Dr. Pavón obtained his Bachelor of Science (Biology) and completed his PhD at the University of Málaga (Málaga, Spain) in 2006 working in the effects of endocannabinoids and analog lipid compounds on obesity and addictive disorders. He moved to The United States of America in 2007, where he worked as a postdoctoral fellow in the Committee on the Neurobiology of Addictive Disorders at The Scripps Research Institute (La Jolla, CA). Dr. Pavón returned to Spain in 2010 and joined the Network of Addictive Disorders as researcher at the IBIMA. In 2015 he reached an PI position and developed new lines of research on the characterization of chemokine signaling systems in the context of addictions and their comorbidities, including psychopathologies and cardiovascular complications. Currently, he is a senior PI who performs translational research in the Cardiology and Cardiac Surgery Unit through the Monardes Program (Andalusian Health System, SAS). Dr. Pavón is interested in the characterization of inflammatory signaling systems associated with obesity and addiction as risk factors for cardiovascular diseases. The main objective of these studies is the identification of biomarkers and therapeutic targets considering the influence of aging and sex differences in the expression of inflammatory factors.

A summary of the scientific production: 100 original articles, 8 review articles, 2 book chapters, participation in 38 competitive projects and 5 patents (PCT extensions) and supervision of 4 PhD students and 1 clinical researcher (Río Hortega Program).

https://www.researchgate.net/profile/Francisco_Javier_Pavon-Moron

ORCID Id: 0000-0002-5256-8904

Researcher ID: AAG-9721-2020

Supervisor Publications

Publications= 105 articles (2015-2020= 76 articles)

See Pavon FJ OR Pavon-Moron OR Javier Pavon in PUBMED

Relevant publications:

• Montesinos J et al. Neuropharmacology. Vol. 162, 107840. (2020). doi: 10.1016/j.neuropharm.2019.107840. 4.367 Impact Factor 2018 JCR: Science, Q1

• Araos P et al. Scientific Reports. Vol. 9(1): 16842 (2019). doi: 10.1038/s41598-019-53312-0. 4.011 Impact Factor 2018 JCR: Science, Q1

• Pavón FJ et al. Addiction Biology. Vol. 24(6), 1204-15 (2019). doi: 10.1111/adb.12695. 4.223 Impact Factor 2018 JCR: Science, D1-Q1

• Sampedro-Piquero P et al. Neuroscience & Biobehavioral Reviews. Vol. 106, 23-48 (2019). doi: 10.1016/j.neubiorev.2018.11.015. 8.002 Impact Factor 2018 JCR: Science, D1-Q1

• Rivera P et al. Pediatric Obesity. Vol. 14(3), e12473 (2019). doi: 10.1111/ijpo.12473. 3.713 Impact Factor 2018 JCR: Science, D1-Q1

• Moreno M et al. Addiction Biology. Vol. 23(6), 1251-61 (2018). doi: 10.1111/adb.12694. 4.223 Impact Factor 2018 JCR: Science, D1-Q1

• Coin Araguez L et al. Scientific Reports. Vol. 8(1):17518 (2018). doi: 10.1038/s41598-018-35759-9. 4.011 Impact Factor 2018 JCR: Science, Q1

• Serrano A et al. Neuropsychopharmacology. Vol. 43(9), 1840-50 (2018). doi: 10.1038/s41386-018-0055-3. 7.160 Impact Factor 2018 JCR: Science, D1-Q1

• Pavon FJ et al. Addiction Biology. Vol. 23(2), 723-34 (2018). doi: 10.1111/adb.12531. 4.223 Impact Factor 2018 JCR: Science, D1-Q1

• Gutiérrez Sacristán A et al. Database: The Journal of Biological Databases and Curation. bax043 (2017). doi: 10.1093/database/bax043. 3.978 Impact Factor 2017 JCR: Science, D1-Q1

• Garcia-Marchena N et al. Addiction Biology. Vol. 22(5), 1366-77 (2017). doi: 10.1111/adb.12408. 5.578 Impact Factor 2017 JCR: Science, D1-Q1

• Castilla-Ortega E et al. Neuroscience & Biobehavioral Reviews. Vol. 66, 15-32 (2016). doi: 10.1016/j.neubiorev.2016.03.030. 8.299 Impact Factor 2016 JCR: Science, D1-Q1

• Castilla-Ortega E and Pavón FJ et al. Neuropharmacology. Vol. 103, 92-103 (2016). doi: 10.1016/j.neuropharm.2015.12.010. 5.012 Impact Factor 2016 JCR: Science, D1-Q1

• Decara J and Pavón FJ E et al. Disease Models & Mechanisms. Vol. 8(10), 1213-25 (2015). doi: 10.1242/dmm.019919. 4.316 Impact Factor 2015 JCR: Science, Q1

• Wulff-Pérez and Pavón FJ et al. Nanomedicine UK. Vol. 9(18), 2761-72 (2014). doi: 10.2217/nnm.14.35. 5.413 Impact Factor 2014 JCR: Science, D1-Q1

• Pavon FJ et al. Addiction Biology. Vol. 18(6), 955-69 (2013). doi: 10.1111/adb.12107. 5.929 Impact Factor 2013 JCR: Science, D1-Q1

• Serrano A and Pavón FJ et al. American Journal of Physiology-Endocrinology and Metabolism. Vol. 302(7), E817-30 (2012). doi: 10.1152/ajpendo.00468.2011. 4.514 Impact Factor 2012 JCR: Science, Q1

• Alonso et al. British Journal of Pharmacology. Vol. 165(7), 2274-91 (2012). eCollection 2012. doi: 10.1111/j.1476-5381.2011.01698.x. 5.067 Impact Factor 2012 JCR: Science, D1-Q1

• Ramchandani VA et al. Molecular Psychiatry. Vol. 16(8), 809-17 (2011). doi: 10.1038/mp.2010.56. 13.668 Impact Factor 2011 JCR: Science, D1-Q1

• Long et al. Nature Chemical Biology. Vol. 5(1), 37-44 (2009). doi: 10.1038/nchembio.129. 16.058 Impact Factor 2009 JCR: Science, D1-Q1

• Cano C and Pavón FJ et al. Journal of Medicinal Chemistry. Vol. 50(2), 389-93 (2007). doi: 10.1021/jm0601102. 4.895 Impact Factor 2007 JCR: Science, D1-Q1

H Index= 23; Citations= 2,250

Patents= 5 with PCT extensions

Active grants= 5 (total project grants= 38)

Supervisor International collaborations:

International Consortium

1. Title: FATZHEIMER: High Fat Diet, Microbiota and Neuroinflammation in the Progression of Alzheimer Disease. Source and code: EU-LAC Health. (EULACH16/T01-0131). Institutions: Instituto IBIMA-FIMABIS (Spain), German Institute of Human Nutrition (Germany), Ministerio de Ciencia, Tecnología e Innovación Productiva (Argentina), P. Catholic University of Chile (Chile), Universidad de la República (Uruguay), University of Coimbra (Portugal). Duration: 01/01/2018-01/01/2021. Funds: 584.481,00 € Coordinator: Fernando Rodríguez de Fonseca.

2. Title: REPROBESITY: Search for New Therapeutic Agents Against Complicated Obesity By Reprofiling Existing Drugs. Source and code: 7th Framework, EU. (HEALTH-F2-2008-223713). Institutions: IBIMA (Spain), Vivia Biotech S.L. (Spain), INSERM (France), Gutenberg-University Mainz (Germany), Universitat di Bologna (Italy), Universidad de Santiago de Compostela (Spain). Duration: 01/12/2008-30/11/2011. Funds: 598,000 €. Coordinator: Fernando Rodríguez de Fonseca.

International Network

1. Management Committee Member for Spain in the COST (European Cooperation in Science and Technology) CA15135-Multi-target paradigm for innovative ligand identification in the drug discovery process (MuTaLig). Participants: 33 COST countries, USA, Brazil. Duration: 2016-2020 extended to 2021. Source: Horizon 2020 Framework Programme (H2020), EU. Funds: 492,136 €. Coordinator: Stefano Alcaro.

In addition to these international consortiums and networks, Dr. Pavón has ongoing collaboration with international research groups such as Dr. Rémi Martin-Fardon and Dr. Marisa Roberto at Scripps Research, La Jolla, USA and Prof. Roberto Ciccocioppo at University of Camerino, Italy.

Supervisor most relevant research projects grants:

Projects as PI

• Title: Stress and alcohol as psychiatric and cardiovascular risk factors associated with inflammation: Antiinflammatory evaluation of the CX3CL1/CX3CR1 signaling system. Source and code: Carlos III Health Institute, Ministry of Economy and Competitiveness, Spain. PI19/00886. Funds: 74,536 €. Duration: 01/2020-01/2023. PI: Francisco Javier Pavón.
• Title: Sex dimorphism in the expression of inflammatory signaling systems of peripheral blood mononuclear cells in patients with alcohol use disorders: Use as biomarkers of addiction. Source and code: National Agency for Drugs, Ministry of Health, Social Services and Equality, Spain. PND2018/033. Funds: 85,000 €. Duration: 01/2019-01/2022. PI: Francisco Javier Pavón.
• Title: Translational study of the CX3CL1/R1 chemokine signaling system in alcohol addiction: Role as neuroinflammatory biomarker. Source and code: Carlos III Health Institute, Ministry of Economy and Competitiveness, Spain. PI16/01953. Funds: 98,615 €. Duration: 01/2017-01/2020. PI: Francisco Javier Pavón.
• Title: Role of the Chemokines CXCL12 (SDF-1) and CX3CL1 (Fractalkine) in the Transition to a Cocaine-Addicted Phenotype as Neuromodulatory Factors and Inflammatory Components. Source and code: Miguel Servet I Program of Carlos III Health Institute, Ministry of Economy and Competitiveness, Spain. CP14/00212. Funds: 98,000 €. Duration: 01/2015-01/2018. PI: Francisco Javier Pavón.
• Title: Identification and characterization of the role of chemokines in cocaine addiction. Source and code: Ministry of Health and Social and Welfare, Junta Andalucía, Spain. PI0228-2013. Funds: 49,941 €. Duration: 01/2014-01/2017. PI: Francisco Javier Pavón.

More information:

• Number of positions available: 1
• Type of contract: Full time contract (2-year contract upon acceptance of the proposal)
• Status: Post-doctoral researcher
• Working hours (hour per week or free text): 35 hours/week
• State / province: Andalucía / Málaga
• City: Málaga
• Postal code: 29010
• Street: Campus Teatinos, sn
• Organisation: IBIMA
• Faculty / department: Cardiology and Cardiac Surgery Unit / Hospital Universitario Virgen de la Victoria
• Country: Spain
• City: Málaga
• State/province: Andalucía / Spain

• Website: www.ibima.eu

• Phone mobile phone: +34 951291169

APPLICATION DETAILS

• Envisaged job starting date: Early 2021 (January to March)
• Application deadline: June 30th, 2020
• How to apply: Please contact Dr. Pavón and send your CV and expression of interest
• Application e-mail: javier.pavon@ibima.eu

REQUIRED EDUCATION LEVEL

• Required education level 1: Health Science (e.g., Biology, Nursing, Pharmacy, Pharmacology....)
• Degree: PhD, MD
• Degree field: Biomedicine, Pharmacology, Molecular mechanisms

REQUIRED EXPERIENCE LEVEL

• Main research field: Molecular biology and/or Pharmacology
• Sub research field: Inflammation, Circulatory system and Translational research
• Years of research experience: 4 or more

REQUIRED LANGUAGES

• Language: English
• Language level: Fluent

ADDITIONAL REQUIREMENTS

• Skills:

Experience in preclinical models (rodents, cultures)

Statistical analysis in biomedicine

Preparation of projects and scientific material

• Specific requirements:

Candidates highly motivated with sense of responsibility, proactivity and capacity for teamwork

At the deadline for the submission of proposals (September 9th, 2020), researchers:

• shall be in possession of a doctoral degree or have at least four years of full-time equivalent research experience.
• must not have resided or carried out their main activities in the country of Spain for more than 12 months in the 3 years immediately prior to the abovementioned deadline.